Syndax Pharmaceuticals: Cancer specialist according to JPMorgan with potential for stock doubling!
Reading Time: 3 minutes
With three FDA approvals in a year, commercialization begins. The treatment of acute leukemia and cGVHD aims to address a market worth over $10 billion. Revuforj expands market potential in relapsed/refractory NPM1m-AML and in the post-transplant setting. The patient potential has already tripled to 6,500. Niktimvo for the treatment of idiopathic pulmonary fibrosis (IPF) could address around 150,000 patients. According to JPMorgan, this opportunity is not yet priced into the stock. Syndax Pharmaceuticals (SNDX) has specialized as an innovative...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
